🇺🇸 FDA
Patent

US 10407468

Methods for synthesizing α4β7 peptide antagonists

granted A61KA61K38/00A61P

Quick answer

US patent 10407468 (Methods for synthesizing α4β7 peptide antagonists) held by Protagonist Therapeutics, Inc. expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Protagonist Therapeutics, Inc.
Grant date
Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K38/00, A61P, A61P1/00, A61P29/00